Different characteristics and survival in non‐small cell lung cancer patients with primary and acquired EGFR T790M mutation-Reference-Cited by-同舟云学术

Different characteristics and survival in non‐small cell lung cancer patients with primary and acquired EGFR T790M mutation

Published:2019-01-03 Issue:11 Volume:144 Page:2880-2886
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Wang Shuyuan¹,Yan Bo¹,Zhang Yanwei¹,Xu Jianlin¹,Qiao Rong¹,Dong Yu¹,Zhang Bo¹,Zhao Yiming¹,Zhang Lele¹,Qian Jie¹,Lu Jun²,Zhao Ruiying³,Han Baohui¹²^ORCID

Affiliation:

1. Department of Pulmonary MedicineShanghai Chest Hospital, Shanghai Jiao Tong University Shanghai China

2. Central LaboratoryShanghai Chest Hospital, Shanghai Jiao Tong University Shanghai China

3. Department of PathologyShanghai Chest Hospital, Shanghai Jiao Tong University Shanghai China

Funder

Shanghai Chest Hospital

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32015

Reference34 articles.

1. Global cancer statistics

2. Global cancer statistics, 2012

3. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The clinicopathological features and possible physiological mechanisms of only the EGFR-T790M primary mutation in patients with lung adenocarcinoma;Pathology - Research and Practice;2024-07

2. Liquid biopsy for the management of NSCLC patients under osimertinib treatment;Critical Reviews in Clinical Laboratory Sciences;2024-02-02

3. The clinicopathological features and possible physiological mechanisms of only EGFR-T790M primary mutation in lung adenocarcinoma patients;2024-01-30

4. Primary versus acquired epidermal growth factor receptor Thr790Met mutant non-small cell lung cancer: clinical features and prognoses;Clinical and Translational Oncology;2024-01-08

5. Genomic heterogeneity of multiple synchronous lung cancers in Chinese population;Cancer Medicine;2024-01